OncoMatch/Clinical Trials/NCT05736965
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
Is NCT05736965 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Selinexor and Azacitidine for aml, adult.
Treatment: Selinexor · Azacitidine · Venetoclax — This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–4(Completely disabled)
Prior therapy
Cannot have received: anti-aml treatment
Exception: hydroxyurea
Lab requirements
Kidney function
creatinine clearance ≥ 30 mL/min (Cockroft-Gault formula)
Liver function
AST ≤ 3.0×ULN; ALT ≤ 3.0×ULN; Bilirubin ≤ 1.5×ULN (≤3.0×ULN if <75 years old); unless due to leukemic organ involvement
Liver function meets the following criteria: aspartate aminotransferase (AST) ≤ 3.0×ULN; alanine aminotransferase (ALT) ≤ 3.0×ULN; Bilirubin≤1.5×ULN; For subjects <75 years old, the bilirubin level can be ≤3.0×ULN; Unless due to leukemic organ involvement. Renal function meets the following criteria: creatinine clearance ≥ 30 mL/min (Cockroft-Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05736965 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages